Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Mirvetuximab Soravtansine
SGO 2022 Annual Meeting on Women’s CancerAdvertisement
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses findings from the SORAYA study on the efficacy and safety of mirvetuximab soravtansine in patients who have platinum-resistant ovarian cancer with high folate receptor–alpha expression. Based on the results, Dr. Matulonis believes this agent might become a practice-changing, biomarker-driven standard-of-care treatment option (Abstract LBA4).
